415917-07-6

Upstream product

• 415917-06-5 4-[cyclopropylmethyl-(3-hydroxy-propyl)-amino]-piperidine 
• 251292-11-2 (R)-N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-methanesulphonyloxy-N-methyl-2-phenyl-acetamide 

Relevant academic research and scientific papers

Pharmaceutical compositions based on anticholinergics and additional active ingredients

A pharmaceutical composition comprising an anticholinergic and at least one additional active ingredient selected from among corticosteroids, dopamine agonistes, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

Method for the treatment or prevention of atopic dermatitis

The invention relates to a method for the treatment or prevention of atopic dermatitis, which comprises the administration of an effective amount of an NK-1 receptor antagonist to a patient in need of such treatment, wherein said NK1 receptor antagonist i

Method for the treatment of prevention of atopic dermatitis

The invention relates to a method for the treatment or prevention of atopic dermatitis, which comprises the administration of an effective amount of an NK-1 receptor antagonist to a patient in need of such treatment, wherein said NK1 receptor antagonist i

Neurokinin antagonists

The invention relates to new compounds of formula I 1or the pharmaceutically acceptable salts thereof, wherein R1 denotes 3-hydroxypropyl, 1,3-dihydroxyprop-2-yl or C3-C6-cycloalkylmethyl, and R2, R3, R4 and Ar have the meanings given in the specification, as well as the preparation and use thereof. The new compounds are valuable neurokinin (tachykinin) antagonists.

Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists

The present invention relates to novel pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists, processes for preparing them and their use in the treatment of respiratory tract diseases.